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Background/aim: Nonalcoholic fatty liver disease (NAFLD) is known to be the most prevalent chronic liver disease all over the world.
The incidence of this disease has dramatically increased during the last decade. Studies have shown a strong relationship between the
level of ferritin and the severity of NAFLD. The objective of the present study was to assess the effect of adding Hijamat, as an iron
reducing procedure, to standard lifestyle modiﬁcation on the improvement of insulin resistance and liver enzymes in patients with
NAFLD.
Materials and methods: One hundred and twenty NAFLD patients participated in a randomized, controlled, single-blind trial design of
study. The control group received counselling for nutrition and physical activity for a period of 6 months. The treatment group received
the above items plus Hijamat for 3 times during 1 month. Ultrasound images of liver, HOMA-IR, and laboratory data including ALT,
AST were assessed pre- and postintervention.
Results: At the end of the study, a signiﬁcant decrease was demonstrated in the serum level of HOMA-IR (–1.30 ± 0.88 vs –.02 ± 0.47,
P < 0.001) and serum levels of ALT (–6.50 ± 4.92 vs –2.38 ± 3.92, P < 0.001) and AST (–2.78 ± 4.29 vs –1.30 ± 2.33, P = 0.021) in the
Hijamat group were compared to the control group. Ultrasound images of the liver improved in 23.3% of the patients in the Hijamat
group, while the rate of improvement in the control group was 10% (P = 0.050). Hijamat therapy was safe and tolerable in this trial.
Conclusions: Hijamat resulted in a relative improvement in fatty liver severity and improved HOMA-IR and liver enzymes more than
lifestyle modification alone in patients with NAFLD.
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1. Introduction
Nonalcoholic fatty liver disease (NAFLD) represents
a spectrum of diseases ranging from steatosis to
steatohepatitis, fibrosis, cirrhosis and even hepatocellular
carcinoma which is characterized by lipid accumulation
within hepatocytes [1]. The incidence of NAFLD has
been increasing during the last 3 decades, reaching
6%–35% in the adult population worldwide [2]. One
of the most important reasons for this high prevalence
is the globalization of sedentary lifestyle and modern
dietary habits together with increased prevalence of
central (abdominal) obesity, type 2 diabetes mellitus,
dyslipidaemia and metabolic syndrome [3].
Although the molecular mechanisms involved in
the pathogenesis of NAFLD are still poorly understood,
insulin resistance contributes to increased delivery of free
fatty acids to the liver and overproduction of lipids in

the liver, eventually leading to NAFLD [4]. According to
various studies, high levels of serum ferritin, as a standard
marker of iron storage are associated with an increase in
free radicals and induce insulin resistance in myocytes,
adipose tissue [5].
Wet cupping therapy or Hijamat is one of the oldest
medical techniques in Asia, the Middle East and Europe. It is
widely referred to Iranian traditional medicine documents
for prevention and treatment of various disorders [6].
In this procedure, causative pathological substances are
excreted from the interstitial ﬂuid and blood in the skin
capillary network after sucking and scariﬁcation steps
[7]. A few studies have suggested that removal of iron by
phlebotomy leads to improved insulin resistance and liver
enzymes in NAFLD patients with normal serum ferritin
and transferrin levels [8,9]. Unlike Hijamat, one of the
superficial veins of the body is cut with a scalpel and some
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blood is removed from the body in phlebotomy [10]. Most
people usually prefer Hijamat to phlebotomy because it
is easier and causes less pain. In light of the cumulative
evidence for the association between serum ferritin and
NAFLD, this study was conducted to evaluate the role of
Hijamat therapy in the improvement of liver enzymes and
HOMA-IR in patients with NAFLD.
2. Materials and methods
2.1. Study design
The study was a randomized, single-blind (observer-blind)
trial and the duration of the study was 6 months. The study
design is depicted in Figure. The patients were randomly
divided to the treatment and control groups using the
stratified blocked randomization method with a computer.
All NAFLD cases initially received counselling to reduce
the intake of carbohydrate, red meat, fried foods, sugars,
and fat and increase fibre intake and physical exercise (at

least 20 min, 3 times per week) as a routine treatment.
After 4 months, the treatment group received Hijamat
for 3 times during 1 month (0 days, 14 days, and 28 days)
[11]. Hijamat was performed using sterile disposable cups
at 5 points: both scapulas, both lumbar regions and vertex.
Disposable cups were placed on these points and negative
pressure was applied by a cupping pump. The cups were
removed after about 2–3 min. Then, 26-gauge disposable
lancets were used for scarification to a depth of 2 mm at
sites of cups. Vacuum pumping was repeated for the second
time and 3–5 cm3 of a bloody excretion was removed per
cupping site. The sites were then covered with sterile pads.
2.2. Study participants
Subjects were selected from those adults aged 18 years
or above consecutively referred to the Gastroenterology
and Hepatology Clinic of the Imam Reza Therapeutic
Educational Hospital (Kermanshah, Iran) with a
diagnosis of NAFLD. This hospital is the largest centre

Assessment of eligibillity (n= 131)

Excluded (n=11)
Not meeting inclusion criteria(n=9)
Declined to participate (n=2)

Randomized (n=120)

Allcocated to intervention (n=60)
lifestyle modification and Hijamat

Assessment at 1th month

Allocated to control (n=60)
lifestyle modification

Assessment at 1th month

Assessment at 6th month
Lost to follow- up
(give to reasons) (n=0)

Assessment at 6th month
Lost to follow- up
(give to reasons) (n=0)

Analyzed (n=60)

Analyzed (60)

Figure. Flow chart of the allocation, follow-up, and analysis of this clinical trial.
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among referral centres in Kermanshah Province, west of
Iran. A diagnosis of NAFLD was made according to the
clinical evidence, liver enzymes and ultrasonography
criteria. All subjects provided informed written consent
for the study. The patients with viral hepatitis B and/or
C infection, jaundice, autoimmune hepatitis, Wilson’s
disease, α-1-antitrypsin deficiency, type 1 or secondary
forms of diabetes, celiac disease, alcohol consumption,
corticosteroids consumption and kidney disorders as well
as pregnant or lactating women were excluded from the
study. Demographic data such as age, sex and medical
history were gathered from patient interviews during
screening.
2.3. Sample size
There were no similar studies to help us with the study
sample size. It has been recommended that around 60
patients are a reasonable sample size for a pilot study to
investigate the treatment effects [12]. Thus, we decided to
recruit at least 60 patients in each group as a convenience
sample.
2.4. Biochemical assessment
Blood samples were collected from participants after a
12-h overnight fast before and after the intervention. After
serum separation, the samples were labelled and stored
at –70 °C until analysis. Enzymatic activities of alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) were measured with the Hitachi 902 autoanalyzer
(Japan) using Pars Azmoon (Iran) analytical kits.
Laboratory reference ranges for ALT and AST were 5-41
IU/L and 5-37 IU/L, respectively. Insulin resistance was
determined using the homeostasis model assessment
(HOMA-IR) by the following formula: fasting insulin (µu/
mL) × fasting glucose (mmoL/dL)/405.
2.5. Ultrasound imaging of the liver
Ultrasound images of each participant were also evaluated
before and after the intervention. Hepatic steatosis was
graded as 0 (no fat accumulation), 1 (minimal increase
in echogenicity along with normal appearance of the
diaphragm and portal vein wall), 2 (moderate increase in
echogenicity along with slightly impaired visualization of
the portal vein wall and diaphragm), and 3 (severe increase
in echogenicity along with poor or no visualization of the
diaphragm, portal vein wall and the posterior portion of
the right hepatic lobe) [13].
2.6. Statistical analysis
The SPSS software was used for statistical analysis version 16
(SPSS Inc., Chicago, IL, USA). The Kolmogorov–Smirnov
test was applied to evaluate the normal distribution of the
data in each group. Continuous variables are presented as
mean ± standard deviation (SD). Independent-samples
t-test or Mann–Whitney U test was used for betweengroup comparisons as appropriate and paired t-test was
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used for within-group comparisons. Categorical variables
were compared using chi-square test. The P < 0.05 was
considered as statistically significant.
3. Results
As shown in Figure, 11 of 131 assessed patients with
NAFLD were excluded from the study for various reasons.
A total of 120 patients (61 males, 59 females) with mean
age of 39.46 ± 8.38 were assessed in this study. The patients
were randomly divided into 2 groups, including 60 patients
in the treatment group and 60 subjects in the control
group. The mean age of the subjects in the treatment and
control group was 38.38 and 40.53 years, respectively (P =
0.161). There were 30 female participants in the treatment
and 29 in the control group. (P = 0.855). There were no
statistical diﬀerences between groups for other baseline
characteristics (P > 0.05), so the groups were comparable.
The patients’ characteristics are described in Table 1.
A paired t‑test showed that after 6 months of Hijamat,
mean ALT, AST and HOMA-IR decreased significantly
from baseline (P < 0.001). In the control group, all
variables after study were significantly decreased compare
to the baseline except for HOMA-IR (P = 0.724) (Table 2).
According to the data shown in Table 3, signiﬁcant
improvements were observed in HOMA-IR and serum
levels of ALT and AST in the treatment group compared
to the control group after the intervention (P < 0.05).
Hijamat was safe and tolerable in this trial and there
were no reports of any side effects. The ultrasonographic
findings of the liver improved significantly in the case
group compared to the control group (P < 0.001). The
fatty liver grade improved in 23.3% of the subjects in the
Hijamat group, while the rate of improvement was 10% in
the control group (Table 4).
4. Discussion
This study was conducted to investigate whether or not
Hijamat therapy is effective in the improvement of liver
enzymes and histology in patients with NAFLD. To the
best of our knowledge, this study is the first published
clinical trial of the effect of a combination of Hijamat and
lifestyle modification on liver enzymes and HOMA-IR
in patients with NAFLD. Therefore, considering the low
number of research articles, we are only able to discuss
the hypothetical mechanisms of Hijamat that may provide
clues to the research question.
The results showed a signiﬁcant improvement in
the serum levels of ALT and AST in the Hijamat group
versus controls. Evidence suggests an association between
increased serum ferritin and ALT levels [14]. Increased
ferritin and body iron stores can lead to advanced fibrosis
in patients with NAFLD [15]. Studies have shown that
iron chelation therapy and Hijamat could be beneficial
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Table 1. Baseline characteristics and biochemical parameters of control and Hijamat groups.
Variables

Control group (n = 60)

Hijamat group (n = 60)

P-value

Age, years

40.53 ± 7.32

38.38 ± 9.26

0.161a

Gender, female (%)

29 (48.33)

30 (50)

0.855b

ALT, IU/L

46.30 ± 4.26

45.88 ± 4.39

0.883c

AST, IU/L

45.46 ± 5.25

44.33 ± 4.79

0.220a

HOMA-IR

2.23 ± 0.62

3.19 ± 0.65

0.630c

Grade I

26 (43.3)

31 (51.7)

0.364b

Grade II

34 (56.7)

28 (46.7)

Grade III

-

1 (1.7)

Sonography (%)

Values are expressed as mean ± SD
a
Independent sample t-test
b
Chi-square test
c
Mann–Whitney U test
Table 2. Comparison between baseline laboratory parameters and after 6 months of intervention.
Variables

Control group

Hijamat group

Baseline

After 6 months

P-value

Baseline

After 6 months

P-value

ALT, IU/L

46.30 ± 4.26

43.91 ± 3.70

<0.001

45.88 ± 4.39

39.38 ± 4.22

<0.001

AST, IU/L

45.46 ± 5.25

44.17 ± 5.74

<0.001

44.33 ± 4.79

41.55 ± 4.43

<0.001

HOMA-IR

2.23 ± 0.62

2.21 ± 0.71

0.724

3.19 ± 0.65

1.89 ± 0.52

<0.001

Data are Mean ±SD.
P values calculated by paired sample t-test
Table 3. Comparison of mean changes in studied variables of 120 patients with
nonalcoholic fatty liver disease.
Variables

Control group

Hijamat group

P-value

Change in ALT, IU/L

–2.38 ± 3.92

–6.50 ± 4.92

<0.001

Change in AST, IU/L

–1.30 ± 2.33

–2.78 ± 4.29

0.021

Change in HOMA-IR

–.02 ± 0.47

–1.30 ± 0.88

<0.001

Data are mean ± SD.
P-values calculated by independent sample t-test.

in patients with mild iron overload. El-Shanshory et al.
(2014) selected 40 thalassaemic children and divided them
into 2 groups: 20 subjects received iron chelation therapy
(ICT) plus Hijamat and 20 patients received iron chelation
therapy as the control group. The authors concluded
that Hijamat could significantly decrease iron overload,
potentiate ICT and decrease oxidative stress. Therefore,

one possible mechanism for therapeutic effects of Hijamat
is the excretion of excess iron in the interstitial ﬂuid [16].
Furthermore, a signiﬁcantly larger improvement was
observed in the HOMA-R index in the case group versus
the control group. Hijamat can decrease oxidative stress
through decreasing the iron stores, resulting in improved
insulin resistance that may lead to decreased production
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Table 4. Evaluation of fatty infiltration in liver tissue after the intervention between studied
groups.
Fatty infiltration

Control group

Hijamat group

P-value

Frequency

Percent

Frequency

Percent

Improved

6

10

14

23.3

Not recovered

54

90

46

76.7

0.050

P-values calculated by chi‑square test.

of liver glucose, which is one of the mechanisms for
developing steatosis in NAFLD. Moreover, oxidative
stress, as a cause of NAFLD, is associated with production
of reactive oxygen species [17], either via peroxisomal
and mitochondrial β-oxidation of hepatic fatty acids
or via inflammatory cell activation. This occurrence
leads to increased lipidperoxidation and the release of
proinflammatory cytokines, resulting in the impairment
of cell membrane integrity [17].
Several studies have evaluated the effect of Hijamat
on different biochemical markers and found that it was
an effective alternative therapy. For example, it has been
suggested that Hijamat can effectively reduce the levels of
cholesterol and LDL and prevent cardiovascular disease
[18]. It is also worth mentioning that there is a significant
positive correlation between increased levels of cholesterol
and LDL and increasing grades of fatty liver [19]. Mahaling
et al. found that individuals with fatty liver had increased
levels of cholesterol, LDL, and very LDL (VLDL) and
decreased levels of HDL [20].
Khodadoostan et al. evaluated the effect of phlebotomy
on liver enzymes and histology in patients with NAFLD.
The authors concluded that phlebotomy decreased liver
cell damage and improved liver enzymes and histology [9].
Another study conducted in Italy evaluated patients with
nonalcoholic fatty liver disease and hyperferritinemia. The
result showed a significant reduction in insulin resistance
following phlebotomy in the treatment group as compared
to the control group [21]. Nevertheless, Hijamat may be
superior to other excretory procedures such as phlebotomy.
Unlike phlebotomy, Hijamat rarely causes anaemia,
as blood cells are not ﬁltered through capillary pores.
Moreover, it filters and clears interstitial ﬂuids from excess
ﬂuids and/or soluble causative pathological substances
that were reported to be rich in iron [10]. Hijamat therapy
is a very safe procedure when performed by trained health
staff. However, few studies have reported some side effects
for cupping therapy, such as persistent skin discoloration,
bruising, scars, burns and infections [22]. Nevertheless,
Hijamat is contraindicated in subjects under 2 and over 60
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years of age and in very slim and weak or extremely obese
individuals [23].
Although Hijamat was more effective on liver
enzymes; the benefits of lifestyle modifications are well
demonstrated. Several studies have shown that permanent
lifestyle changes induce weight loss and improve liver
enzymes and histological outcomes in NAFLD [24,25].
Several points should be considered as the strengths
of this study such as its novelty in introducing a safe and
affordable therapy for improvement of liver enzymes and
histology in patients with NAFLD. However, the study
also had several limitations like not assessing many fatty
liver biochemical markers such as oxidative stress, serum
lipid profile and serum and liver iron levels, a short followup period, and lack of daily assessment of calorie intake
by patients. Also due to the nature of Hijamat, it is not
possible to blind participants to performed intervention.
Taken together, the results of this study implied that
Hijamat was a safe and economic, and the complementary
use of Hijamat plus lifestyle modification could be more
effective in reducing HOMA-IR and ALT and AST levels
and improve the fatty liver grade.
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